Markets:

Overview

News

Currencies

International

Treasuries

Daiichi Sankyo CO Ltd Ord (OP:DSKYF)

18.84 +1.45 (+8.30%)

Streaming Delayed Price Updated: 2:36 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo CO Ltd Ord

< Previous 1 2 Next >

AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study ↗

August 15, 2022

Via Benzinga

Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation ↗

August 12, 2022

Via Benzinga

AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients ↗

August 09, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting ↗

July 19, 2022

Via Benzinga

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗

June 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies ↗

June 27, 2022

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, June 6 ↗

June 06, 2022

Reuters

Via Benzinga

AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50% ↗

June 06, 2022

Via Benzinga

FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer ↗

May 05, 2022

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer ↗

April 27, 2022

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer ↗

April 19, 2022

Via Benzinga

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case ↗

April 11, 2022

A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)

Via Benzinga

AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting ↗

February 22, 2022

AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2...

Via Benzinga

Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters ↗

October 18, 2021

Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a...

Via Benzinga

AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials ↗

September 20, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor...

Via Benzinga

AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer ↗

September 17, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu...

Via Benzinga

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗

August 09, 2021

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3...

Via Benzinga

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu ↗

July 08, 2021

Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (...

Via Benzinga

Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan ↗

June 15, 2021

Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the...

Via Benzinga

Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters ↗

May 26, 2021

Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro...

Via Benzinga

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer ↗

May 10, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program...

Via Benzinga

LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates ↗

April 27, 2021

CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.